These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases. Gonzalez-Rodriguez A; Valverde AM Curr Pharm Des; 2015; 21(31):4574-86. PubMed ID: 26486144 [TBL] [Abstract][Full Text] [Related]
4. RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease. Strnad P; San Martin J Expert Opin Investig Drugs; 2023; 32(7):571-581. PubMed ID: 37470509 [TBL] [Abstract][Full Text] [Related]
5. An update on the therapeutic role of RNAi in NAFLD/NASH. Dehghan H; Ghasempour A; Sabeti Akbar-Abad M; Khademi Z; Sedighi M; Jamialahmadi T; Sahebkar A Prog Mol Biol Transl Sci; 2024; 204():45-67. PubMed ID: 38458743 [TBL] [Abstract][Full Text] [Related]
6. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies? La Sala L; Carlini V; Conte C; Macas-Granizo MB; Afzalpour E; Martin-Delgado J; D'Anzeo M; Pedretti RFE; Naselli A; Pontiroli AE; Cappato R Pharmacol Res; 2024 Mar; 201():107083. PubMed ID: 38309383 [TBL] [Abstract][Full Text] [Related]
7. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
8. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and therapy of inheritable liver diseases: hemochromatisis, Wilson's disease and alpha-1-antitrypsin deficiency]. Strassburg ChP Praxis (Bern 1994); 2005 Jan; 94(3):73-81. PubMed ID: 15719801 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Goga A; Stoffel M Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608 [TBL] [Abstract][Full Text] [Related]
14. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases. Ossipov DA Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142 [TBL] [Abstract][Full Text] [Related]
15. RNAi-based therapeutic strategies for metabolic disease. Czech MP; Aouadi M; Tesz GJ Nat Rev Endocrinol; 2011 Apr; 7(8):473-84. PubMed ID: 21502982 [TBL] [Abstract][Full Text] [Related]
16. Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin. Gogate A; Belcourt J; Shah M; Wang AZ; Frankel A; Kolmel H; Chalon M; Stephen P; Kolli A; Tawfik SM; Jin J; Bahal R; Rasmussen TP; Manautou JE; Zhong XB Pharmacol Rev; 2023 Dec; 76(1):49-89. PubMed ID: 37696583 [TBL] [Abstract][Full Text] [Related]